NB 303
Alternative Names: NB-303Latest Information Update: 15 Jan 2024
At a glance
- Originator Neologics Bioscience
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 30 Nov 2023 Preclinical trials in Solid tumours in China (Parenteral) (Neologics Bioscience pipeline, November 2023)